Prometic Life Scienc (PFSCF) 0.9060 $PFSCF
Global Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2014 - Analysis of 24 Companies & 31 Drug Profiles
M2 - Mon Apr 28, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dwrzr/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Novo Nordisk A/S - Mochida Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Genfit SA - Orchid Chemicals & Pharmaceuticals Ltd - La Jolla Pharmaceutical Company - ProMetic Life Sciences Inc. - Immuron Limited - Phenex Pharmaceuticals AG - Wellstat Therapeutics Corporation - Zafgen Inc. - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Obio Pharmaceutical Holdings Limited - Tobira Therapeutics, Inc. - Jenken Biosciences, Inc - Kyorin Pharmaceutical Co., Ltd. - NasVax Ltd. - Stelic Institute & Co. - Galmed International Ltd. - Connexios Life Sciences Pvt. Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - GFT-505 - KD-025 - obeticholic acid - liraglutide - Aramchol - emricasan - atorvastatin calcium - Anti-CD3 Oral Immunotherapy - IMM-124E - Px-102 - icosapent ethyl - BLX-1002 - tranilast - Px-104 - tipelukast - GR-MD-02 - GCS-100 - cenicriviroc - PN-2XXX - JKB-121 - JKB-119 - AK-20 - PBI-4050 - CNXFC-010 - ISIS-DGAT2Rx - ZGN-839 - remogliflozin etabonate - Small Molecule to Inhibit SCD-1 for NASH - Px-103 - STNM-09 For more information visit http://www.researchandmarkets.com/research/7d...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Chemotherapy Induced Anemia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tk5t2k/chemotherapy) has announced the addition of the "Global Chemotherapy Induced Anemia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - 3SBio Inc. - ProMetic Life Sciences Inc. - Avesthagen Limited - Therapure Biopharma Inc. - Tarix Pharmaceuticals LTD. - Aprogen, Inc. - Tolero Pharmaceuticals, Inc. - SBI Pharmaceuticals Co., Ltd. Drug Profiles - epoetin alfa biosimilar - PBI-1402 - NuPIAO - LY-2787106 - Drug For Chemotherapy Induced Anemia - darbepoetin alfa biosimilar - PanCyte - PBI-4494 - TBI-304 - darbepoetin alfa biosimilar - TP-0413 - PBI-1402 For more information visit http://www.researchandmarkets.com/research/tk...hemotherap
Global Renal Anemia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dsdt5s/renal_anemia) has announced the addition of the "Global Renal Anemia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development: - Hospira, Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited - Bayer AG - Zosano Pharma, Inc. - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Acceleron Pharma, Inc. - Pieris AG - Aprogen, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles - peginesatide - darbepoetin alfa - roxadustat - epoetin zeta - epoetin alfa - FG-2216 - roxadustat - sotatercept - GSK-1278863 - PBI-1402 - molidustat - JTZ-951 - PEG-EPO - FG-2216 - PRS-080 - NuPIAO - epoetin alfa - JTZ-951 - erythropoietin biosimilar - DS-1093 - PBI-4050 - ZP-EPO - darbepoetin alfa biosimilar - MM-P01-01 - Recombinant Protein for Anaemia with Chronic Renal Failure For more information visit http://www.researchandmarkets.com/research/ds...nal_anemia
Neutropenia Therapeutic Pipeline Review 2014 - Analysis of 16 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl9vgd/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Hospira, Inc. - Gamida Cell Ltd. - Ligand Pharmaceuticals, Inc. - Cleveland BioLabs, Inc. - Telik, Inc. - ProMetic Life Sciences Inc. - Green Cross Corporation - Cellerant Therapeutics, Inc. - Genexine, Inc. - Bolder Biotechnology, Inc. - USV Limited - Pfenex Inc. - Mycenax Biotech Inc. - NAL Pharmaceuticals Ltd. - Inbiopro Solutions Pvt. Ltd. - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - GCPGC - filgrastim biosimilar - MG-1107 - ezatiostat hydrochloride - HM-10460A - GC-003 - romyelocel L - Human Serum Albumin Fusion Protein Drug - GX-G3 - filgrastim - pegfilgrastim biosimilar - filgrastim biosimilar - CBLB-612 - PBI-4050 - BBT-015 - BBT-018 - BBT-007 - pegfilgrastim biosimilar - IBPB-004-IG - LG-7455 - ACN-8337 - pegfilgrastim biosimilar - Pegylated Granulocyte Colony Stimulating Factor Biosimilar - granulocyte colony-stimulating factor biobetter - Hemokine For more information visit http://www.researchandmarkets.com/research/sl...eutropenia
ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver Fibrosis and Liver Cancer
Marketwire - Thu Apr 10, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
presented new pre-clinical data at the 2014 annual meeting of the European Association for the Study of the Liver ("EASL" currently being held in London, UK. The new data supports the claim that PBI-4050's anti-fibrotic activity could also address various liver conditions such as non-alcoholic steatohepatitis ("NASH" , a condition affecting 2% to 5% of Americans, as well as liver cancer.
ProMetic's PBI-4050 Shown to Reduce Blood Glucose and Kidney Fibrosis in Preclinical Models of Human Type II Diabetes and Kidney Disease
Marketwire - Thu Apr 03, 8:04AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation" presented new pre-clinical data at the 2014 International Society of Nephrology ("lSN" : Nexus Symposium - New Era of Drug Discovery and Clinical Trials in Kidney Disease held in Bergamo, Italy on April 3-6, 2014.
ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA" for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture.
ProMetic Reports its 2013 Fourth Quarter and Financial Year End Results and Business Highlights
Marketwire Canada - Wed Mar 26, 4:11PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX
FSCF) ("ProMetic" or the "Corporation" today reported revenues of $5.1 million and $20.6 million for the quarter and year ended December 31, 2013 respectively. This compares to revenues of $8.3 million and $23.3 million for the quarter and year ended December 31, 2012 respectively.
ProMetic to Report its Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call/Webcast
Marketwire - Fri Mar 21, 11:55AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013 on Wednesday March 26, 2014 after market trading hours.
ProMetic Receives $3.2 Million Via Loan Repayment
Marketwire - Tue Mar 11, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today that it has received approximately $3.2 million via the repayment of the amended and restated loan entered into in March, 2010 by ProMetic and InvHealth Holding Inc. ("Invhealth" , a corporation wholly-owned and controlled by Mr. Pierre Laurin, President and Chief Executing Officer of ProMetic (the "Loan" .
Avivagen Announces Nomination of New Director Mr. G.F. Kym Anthony Standing for Election
ACCESSWIRE - Fri Feb 28, 7:02AM CST
OTTAWA, ONTARIO / February 28, 2014 / ACCESSWIRE / Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the nomination of a new Director, Mr. G.F. Kym Anthony, and the retirement of its current Chairman, Mr. Jacques Brault.
ProMetic Enters Into $1.6 Million Development Agreement With New Client
Marketwire - Thu Feb 06, 12:25PM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL" , has entered into a new agreement with a leading vaccines company, for the development of an affinity adsorbent and associated purification process for the production of a novel vaccine product.
ProMetic Announces the Appointment of its New Chief Medical Officer
Marketwire - Thu Feb 06, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today the appointment of Dr. John Moran as its new Chief Medical Officer ("CMO" , effective as of March 1st, 2014.
Global Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2014 - Analysis of 24 Companies & 31 Drug Profiles
M2 - Mon Apr 28, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dwrzr/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Novo Nordisk A/S - Mochida Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Genfit SA - Orchid Chemicals & Pharmaceuticals Ltd - La Jolla Pharmaceutical Company - ProMetic Life Sciences Inc. - Immuron Limited - Phenex Pharmaceuticals AG - Wellstat Therapeutics Corporation - Zafgen Inc. - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Obio Pharmaceutical Holdings Limited - Tobira Therapeutics, Inc. - Jenken Biosciences, Inc - Kyorin Pharmaceutical Co., Ltd. - NasVax Ltd. - Stelic Institute & Co. - Galmed International Ltd. - Connexios Life Sciences Pvt. Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - GFT-505 - KD-025 - obeticholic acid - liraglutide - Aramchol - emricasan - atorvastatin calcium - Anti-CD3 Oral Immunotherapy - IMM-124E - Px-102 - icosapent ethyl - BLX-1002 - tranilast - Px-104 - tipelukast - GR-MD-02 - GCS-100 - cenicriviroc - PN-2XXX - JKB-121 - JKB-119 - AK-20 - PBI-4050 - CNXFC-010 - ISIS-DGAT2Rx - ZGN-839 - remogliflozin etabonate - Small Molecule to Inhibit SCD-1 for NASH - Px-103 - STNM-09 For more information visit http://www.researchandmarkets.com/research/7d...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Chemotherapy Induced Anemia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tk5t2k/chemotherapy) has announced the addition of the "Global Chemotherapy Induced Anemia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - 3SBio Inc. - ProMetic Life Sciences Inc. - Avesthagen Limited - Therapure Biopharma Inc. - Tarix Pharmaceuticals LTD. - Aprogen, Inc. - Tolero Pharmaceuticals, Inc. - SBI Pharmaceuticals Co., Ltd. Drug Profiles - epoetin alfa biosimilar - PBI-1402 - NuPIAO - LY-2787106 - Drug For Chemotherapy Induced Anemia - darbepoetin alfa biosimilar - PanCyte - PBI-4494 - TBI-304 - darbepoetin alfa biosimilar - TP-0413 - PBI-1402 For more information visit http://www.researchandmarkets.com/research/tk...hemotherap
Global Renal Anemia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dsdt5s/renal_anemia) has announced the addition of the "Global Renal Anemia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development: - Hospira, Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited - Bayer AG - Zosano Pharma, Inc. - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Acceleron Pharma, Inc. - Pieris AG - Aprogen, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles - peginesatide - darbepoetin alfa - roxadustat - epoetin zeta - epoetin alfa - FG-2216 - roxadustat - sotatercept - GSK-1278863 - PBI-1402 - molidustat - JTZ-951 - PEG-EPO - FG-2216 - PRS-080 - NuPIAO - epoetin alfa - JTZ-951 - erythropoietin biosimilar - DS-1093 - PBI-4050 - ZP-EPO - darbepoetin alfa biosimilar - MM-P01-01 - Recombinant Protein for Anaemia with Chronic Renal Failure For more information visit http://www.researchandmarkets.com/research/ds...nal_anemia
Neutropenia Therapeutic Pipeline Review 2014 - Analysis of 16 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl9vgd/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Hospira, Inc. - Gamida Cell Ltd. - Ligand Pharmaceuticals, Inc. - Cleveland BioLabs, Inc. - Telik, Inc. - ProMetic Life Sciences Inc. - Green Cross Corporation - Cellerant Therapeutics, Inc. - Genexine, Inc. - Bolder Biotechnology, Inc. - USV Limited - Pfenex Inc. - Mycenax Biotech Inc. - NAL Pharmaceuticals Ltd. - Inbiopro Solutions Pvt. Ltd. - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - GCPGC - filgrastim biosimilar - MG-1107 - ezatiostat hydrochloride - HM-10460A - GC-003 - romyelocel L - Human Serum Albumin Fusion Protein Drug - GX-G3 - filgrastim - pegfilgrastim biosimilar - filgrastim biosimilar - CBLB-612 - PBI-4050 - BBT-015 - BBT-018 - BBT-007 - pegfilgrastim biosimilar - IBPB-004-IG - LG-7455 - ACN-8337 - pegfilgrastim biosimilar - Pegylated Granulocyte Colony Stimulating Factor Biosimilar - granulocyte colony-stimulating factor biobetter - Hemokine For more information visit http://www.researchandmarkets.com/research/sl...eutropenia
ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver Fibrosis and Liver Cancer
Marketwire - Thu Apr 10, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
presented new pre-clinical data at the 2014 annual meeting of the European Association for the Study of the Liver ("EASL" currently being held in London, UK. The new data supports the claim that PBI-4050's anti-fibrotic activity could also address various liver conditions such as non-alcoholic steatohepatitis ("NASH" , a condition affecting 2% to 5% of Americans, as well as liver cancer. ProMetic's PBI-4050 Shown to Reduce Blood Glucose and Kidney Fibrosis in Preclinical Models of Human Type II Diabetes and Kidney Disease
Marketwire - Thu Apr 03, 8:04AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"
presented new pre-clinical data at the 2014 International Society of Nephrology ("lSN" : Nexus Symposium - New Era of Drug Discovery and Clinical Trials in Kidney Disease held in Bergamo, Italy on April 3-6, 2014. ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA" for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture. ProMetic Reports its 2013 Fourth Quarter and Financial Year End Results and Business Highlights
Marketwire Canada - Wed Mar 26, 4:11PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX
FSCF) ("ProMetic" or the "Corporation" today reported revenues of $5.1 million and $20.6 million for the quarter and year ended December 31, 2013 respectively. This compares to revenues of $8.3 million and $23.3 million for the quarter and year ended December 31, 2012 respectively. ProMetic to Report its Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call/Webcast
Marketwire - Fri Mar 21, 11:55AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013 on Wednesday March 26, 2014 after market trading hours. ProMetic Receives $3.2 Million Via Loan Repayment
Marketwire - Tue Mar 11, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today that it has received approximately $3.2 million via the repayment of the amended and restated loan entered into in March, 2010 by ProMetic and InvHealth Holding Inc. ("Invhealth" , a corporation wholly-owned and controlled by Mr. Pierre Laurin, President and Chief Executing Officer of ProMetic (the "Loan" . Avivagen Announces Nomination of New Director Mr. G.F. Kym Anthony Standing for Election
ACCESSWIRE - Fri Feb 28, 7:02AM CST
OTTAWA, ONTARIO / February 28, 2014 / ACCESSWIRE / Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the nomination of a new Director, Mr. G.F. Kym Anthony, and the retirement of its current Chairman, Mr. Jacques Brault.
ProMetic Enters Into $1.6 Million Development Agreement With New Client
Marketwire - Thu Feb 06, 12:25PM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL" , has entered into a new agreement with a leading vaccines company, for the development of an affinity adsorbent and associated purification process for the production of a novel vaccine product. ProMetic Announces the Appointment of its New Chief Medical Officer
Marketwire - Thu Feb 06, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
announced today the appointment of Dr. John Moran as its new Chief Medical Officer ("CMO" , effective as of March 1st, 2014. 
